Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Influence of B Cell Depletion by Anti-CD20 Antibodies in Systemic Scleroderma
2008-007180-16Phase 2Active
- Sponsor
- Leiden University Medical Center
- Start
- Nov 2008
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, single-arm trial of rituximab in systemic sclerosis (SSc), sponsored by Leiden University Medical Center. Primary endpoints: Treatment-related mortality, Treatment toxicity and 1 more. Started Nov 2008; status: active.
02
Drugs
rituximab
03
Conditions
systemic sclerosis (SSc)
Beyond the preview
Go deeper on 2008-007180-16.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-007180-16.